Skip to Content

Resverlogix Corp RVXCF

Morningstar Rating
$0.05 0.00 (3.16%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RVXCF is trading at a 35% discount.
Price
$0.05
Fair Value
$5.32
Uncertainty
Extreme
1-Star Price
$9.26
5-Star Price
$8.32
Economic Moat
Zgywp
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RVXCF is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.05
Day Range
$0.050.05
52-Week Range
$0.040.20
Bid/Ask
$0.04 / $0.07
Market Cap
$12.52 Mil
Volume/Avg
6,000 / 15,255

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
19

Valuation

Metric
RVXCF
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
RVXCF
Quick Ratio
0.01
Current Ratio
0.11
Interest Coverage
−6.81
Quick Ratio
RVXCF

Profitability

Metric
RVXCF
Return on Assets (Normalized)
−101.59%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
RVXCF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRRwvr$541.4 Bil
VRTX
Vertex Pharmaceuticals IncLphgl$110.3 Bil
REGN
Regeneron Pharmaceuticals IncBbcdpy$108.4 Bil
MRNA
Moderna IncXqd$37.2 Bil
ARGX
argenx SE ADRWrg$23.7 Bil
BNTX
BioNTech SE ADRDgmj$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncDwdhhv$19.5 Bil
BMRN
Biomarin Pharmaceutical IncThnkmh$16.7 Bil
RPRX
Royalty Pharma PLC Class APlkqkrf$13.7 Bil
INCY
Incyte CorpXcmzg$13.5 Bil

Sponsor Center